Company / Cash & Equivalents
HealthLynked Corp Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$76.2K
FY2024
5-year range
$76.2K / $3.3M
FY2020-FY2024
Trend
-69.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $3M to $76,241 over the past 3 years.
Based on SEC 10-K filings.
$76,241 in FY2024 with a 3-year CAGR of -71.5%.
Declined from $3M to $76,241 over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -71.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -71.5%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 69.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -24.77 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $76.2K | -69.2% |
| FY2023 | $247.2K | - |
| FY2022 | - | - |
| FY2021 | $3.3M | +1929.6% |
| FY2020 | $162.2K | - |